Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Frontiers in oncology·2026

Same author

Altered development in auditory white matter and cortical response latency in youth with neurofibromatosis type I.

Neuroreport·2026

Same author

Visual morbidity, long-term outcome and prognostic factors in infants and young children with optic pathway low-grade glioma.

Neuro-oncology practice·2026

Same author

Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Frontiers in oncology·2026

Same author

Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.

Neuro-oncology·2026

Same author

Management of adverse events in patients with pediatric low-grade glioma treated with MAPK-directed therapies: Delphi consensus recommendations and unmet needs.

Neuro-oncology practice·2026

Same journal

Cancer immunotherapy with oncolytic myxoma virus.

Advances in cancer research·2026

Same journal

Cancer terminator viruses: Unique conditionally replication competent oncolytic viruses producing therapeutic anti-cancer immunomodulating agents.

Advances in cancer research·2026

Same journal

Advancing clinical translation of oncolytic adenoviruses.

Advances in cancer research·2026

Same journal

Operation oncolysis: Reoviruses in the theater of cancer war.

Advances in cancer research·2026

Same journal

AAV vectors for cancer gene therapy.

Advances in cancer research·2026

Same journal

Vesicular stomatitis virus (VSV) as an oncolytic therapeutic agent for cancer.

Advances in cancer research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 12, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

Pediatric-Type Diffuse Low Grade Glioma.

Chelsea Kotch¹, Katherine Green², Michael J Fisher¹

¹Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, United States; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.

Advances in Cancer Research

|November 6, 2025

Summary

This summary is machine-generated.

Pediatric-type diffuse low grade gliomas are a new group of brain tumors. Accurate diagnosis requires combining histology and molecular data for effective management.

Keywords:

Angiocentric glioma Central nervous system tumors Pediatric-type diffuse low grade glioma Polymorphous low-grade neuroepithelial tumor of the young

More Related Videos

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

Related Experiment Videos

Last Updated: Jan 12, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

Area of Science:

Neuro-oncology
Pediatric Pathology
Molecular Diagnostics

Background:

The WHO 2021 classification introduces pediatric-type diffuse low grade gliomas as a distinct subgroup.
This group includes four entities: diffuse astrocytoma MYB/MYBL1-altered, angiocentric glioma, polymorphous low-grade neuroepithelial tumor of the young, and diffuse low grade glioma MAPK-altered.
Histopathology and molecular alterations show significant overlap, complicating diagnosis.

Purpose of the Study:

To describe the epidemiologic, imaging, and molecular features of these pediatric diffuse gliomas.
To review current management approaches and treatment outcomes.
To explore potential therapeutic implications of molecular alterations.

Main Methods:

Review of epidemiologic data.
Analysis of imaging characteristics.
Integration of molecular findings with histopathology.
Literature review of management and treatment outcomes.

Main Results:

Detailed characterization of the four entities within the pediatric-type diffuse low grade glioma family.
Emphasis on the necessity of integrated diagnostic approaches.
Summary of current treatment strategies and outcomes.
Identification of key molecular alterations and their therapeutic relevance.

Conclusions:

Accurate diagnosis of pediatric-type diffuse low grade gliomas necessitates a combined histological and molecular approach.
Understanding the unique features of each entity is crucial for tailored management.
Molecular alterations offer potential targets for novel therapeutic strategies.